引用本文:蓝 梅,高清平.异基因造血干细胞移植治疗重症再生障碍性贫血的评价[J].中国临床新医学,2011,4(8):721-724.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 1493次   下载 947 本文二维码信息
码上扫一扫!
分享到: 微信 更多
异基因造血干细胞移植治疗重症再生障碍性贫血的评价
蓝 梅,高清平
430060 湖北,武汉大学人民医院血液内科
摘要:
[摘要] 目的 评价以环磷酰胺(CTX)为预处理方案行异基因造血干细胞移植(Allo-HSCT)治疗重症再生障碍性贫血(SAA)的疗效。方法 对1例SAA患者行同胞供者Allo-HSCT治疗。预处理方案为CTX 50 mg/kg-1·d-1×4 d;干细胞来源采用外周血+骨髓;输注单个核细胞数(MNC)为10.41×108/kg,CD34+细胞计数为6.86×106/kg。预防移植物抗宿主病(GVHD)采用环孢素A(CsA)加短程甲氨蝶呤(MTX)加霉酚酸酯(MMF)。结果 患者获得造血重建,第14天中性粒细胞数(ANC)≥0.5×109/L、血小板计数(PLT)≥20×109/L,第96天血型转变为供者型(B→O)。患者出现Ⅳ度急性GVHD(aGVHD),经积极治疗后控制。150 d内患者出现急性化脓性扁桃体炎、口腔溃疡、急性支气管炎、带状疱疹病毒感染、巨细胞病毒血症、肺炎,经积极治疗后均好转。随访24个月,患者无病存活。结论 以CTX为预处理方案allo-HSCT是治愈SAA的一种有效方法。
关键词:  重症再生障碍性贫血  异基因  造血干细胞移植  预处理
DOI:10.3969/j.issn.1674-3806.2011.08.09
分类号:R 556.5
基金项目:
Allogeneic hemapoietic stem cell transplantation for severe aplastic anaemia
LAN Mei,GAO Qing-ping
Department of Hematology,the People′s Hospital of Wuhan Univiersity, Wuhan 430060, China
Abstract:
[Abstract] Objective To evaluate the clinical effect of allogeneic hemapoietic stem cell transplantation(Allo-HSCT) with cyclophosphamide (Cy) as conditioning regimen for severe aplastic anaemia(SAA). Methods One patient with SAA received HLA matched allo-HSCT. Conditioning regimen was Cy 50 mg/kg-1 · d-1×4 d. The peripheral blood stem cells (PBSC) + bone marrow stem cells (BMSC) were used as the source of grafts. The infused number of mononuclear cells were 10.41×108/kg and the number of CD34(+) cells were 6.86×106/kg. Cyclosporine A (CsA) and short-course methotrexate(MTX ) and mycophenlate mofetil(MMF) were administered to prevent the graft versus host disease(GVHD). Results The patient was engrafted. The time for granulocyte count 0.5×109/L and platelet count 20×109/L were 14 days. The blood type was changed into the type donor(B→O) in +96 days. Grade Ⅳ aGVHD developed and was controlled in the patient. Acute suppurative tonsillitis, dental ulcer, acute bronchitis, herpes zoster virus infection, cytomegalovirus viremia and peeumonia occurred in 150 days after allo-HSCT, and these complications were properly disposed. With follow-up of 24 months, the patient survived with disease free. Conclusion Allo-HSCT with cyclophosphamide as conditioning regimens is a method for curing the patient with SAA.
Key words:  Severe aplastic anaemia  Allogene  Stem cell transplantation  Conditioning regimen